Fractyl Health

Fractyl Health develops innovative medical device solutions for the treatment of chronic diseases. The growing product pipeline leverages our minimally invasive procedural therapy, Revita DMR (duodenal mucosal resurfacing), which is designed to rejuvenate the lining of the duodenum and improve patient health. They envision a world with better solutions to chronic diseases through the use of less invasive, device-based therapies that will lessen the burden on patients, physicians, and payers.

Fractyl Health aims to bring curative therapies to the large populations of patients with metabolic disease.

Fractyl Health headquartered in United States, North America, operates in the Biotechnology, Health Care, Medical Device, Therapeutics sector. The company focuses on Biotechnology and has secured $32.7B in funding across 128 round(s). With a team of 51-100 employees, Fractyl Health is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Fractyl Health, raised $14.3M. Discover more about their projects, partnerships, and impact on our platform.